Michael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.
Michael S. Leapman, MD, MHS
Advertisement
Articles by Michael S. Leapman, MD, MHS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5